Glycomine Gets $115M Series C for Rare Disease, Aims for Phase II Launch Mid-Year

The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a rare disease that affects the entire body and produces a wide range of symptoms.